CLINICAL TRIALS PROFILE FOR TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

All Clinical Trials for TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	Canadian Institutes of Health Research (CIHR)	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	McGill University Health Center	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	McGill University Health Centre/Research Institute of the McGill University Health Centre	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT00313807 ↗	Study of Intravenous Amino Acid Infusion to Prevent Contrast Dye Mediated Renal Damage	Withdrawn	Queen's University	Phase 2	2005-11-01	Exposure to radiographic contrast dye during coronary angiography is well known to cause either transient decreases in renal function or acute renal failure. Although the overall incidence is low, acute renal failure occurs most frequently in patients with both diabetes and chronic renal failure where the average reported incidence is upwards of 20%. The etiology of contrast-induced nephropathy is related to acute decline in renal blood flow following dye exposure resulting in ischemic injury at the level of the medulla. The development of acute renal failure following radiocontrast dye administration is significant because it contributes to morbidity and mortality in patients at risk. The administration of amino acids, either through intravenous infusion or a protein meal, results in a substantial increase in renal plasma flow (RPF) and glomerular filtration rate (GFR). In both healthy subjects and in those with chronic renal failure, an amino acid infusion produces a 20% rise in GFR and effective RPF. We hypothesize that the 20% rise in effective RPF and GFR following an amino acid infusion will counteract the radiocontrast dye-induced vasoconstriction and reduce the renal toxicity of contrast medium in a group of high-risk patients.

Clinical Trial Conditions for TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

Condition Name

Condition Name for TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
Intervention	Trials
Colorectal Cancer	1
Contrast Nephropathy	1
Renal Failure	1

Condition MeSH

Condition MeSH for TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
Intervention	Trials
Colorectal Neoplasms	1
Renal Insufficiency	1
Kidney Diseases	1

Clinical Trial Locations for TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

Trials by Country

+

−

Trials by Country for TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
Location	Trials
Canada	1

Clinical Trial Progress for TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Active, not recruiting	1
Withdrawn	1

Clinical Trial Sponsors for TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
Sponsor	Trials
Queen's University	1
Canadian Institutes of Health Research (CIHR)	1
McGill University Health Center	1

Sponsor Type

Sponsor Type for TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
Sponsor	Trials
Other	4

TRAVASOL 4.25% in Dextrose 20%: Clinical Trials, Market Analysis, and Future Projections

TRAVASOL 4.25% in Dextrose 20% is a critical parenteral nutrition solution used in healthcare settings. This article delves into the latest clinical trials, market trends, and future projections for this essential medical product.

Understanding TRAVASOL 4.25% in Dextrose 20%

TRAVASOL 4.25% in Dextrose 20% is a sterile, nonpyrogenic solution of amino acids and dextrose in water for injection. It's primarily used for parenteral nutrition in patients who require intravenous feeding due to various medical conditions[1].

Composition and Usage

The solution contains essential and non-essential amino acids, along with a high concentration of dextrose. It's typically administered through a central vein, providing patients with necessary nutrients when oral or enteral nutrition is not possible or sufficient[1].

Clinical Significance

Parenteral nutrition solutions like TRAVASOL 4.25% in Dextrose 20% play a crucial role in maintaining nutritional status in critically ill patients, post-surgical recovery, and various other clinical scenarios where normal feeding is compromised.

Recent Clinical Trials and Studies

While specific recent trials for TRAVASOL 4.25% in Dextrose 20% are not directly mentioned in the provided search results, we can draw insights from related studies on parenteral nutrition solutions.

Comparative Studies

A historical clinical trial compared Travasol 8.5% without electrolytes to FreAmine II 8.5%. The study, involving 36 patients, found that both solutions could promote positive nitrogen balance in patients with normal renal and hepatic function, with no significant differences in metabolic complications[9].

Based on these results, the use of either FreAmine II or Travasol can promote positive nitrogen balance in a TPN patient population with normal renal and hepatic function with no difference in metabolic complications[9].

Ongoing Research

While not specific to TRAVASOL 4.25% in Dextrose 20%, ongoing research in the field of parenteral nutrition continues to explore optimal formulations, administration protocols, and patient outcomes.

Market Analysis

The market for parenteral nutrition solutions, including TRAVASOL 4.25% in Dextrose 20%, is influenced by various factors.

Current Market Status

As of 2024, TRAVASOL 4.25% in Dextrose 20% remains a significant player in the parenteral nutrition market. The product is listed in the FDA's Orange Book, indicating its approved status under section 505 of the Federal Food, Drug, and Cosmetic Act[10].

Supply Chain Insights

A 2024 supply availability report indicates that various parenteral nutrition solutions, including amino acid and dextrose combinations, are generally available through distributors, wholesalers, and direct shipments[4].

Regulatory Landscape

The FDA closely regulates manufacturers of products like TRAVASOL 4.25% in Dextrose 20% to ensure compliance with relevant laws and regulations[2].

Future Projections

While specific projections for TRAVASOL 4.25% in Dextrose 20% are not provided in the search results, we can infer potential trends based on the broader parenteral nutrition market.

Technological Advancements

Ongoing research and development in the field of parenteral nutrition may lead to improved formulations, potentially enhancing the efficacy and safety profile of products like TRAVASOL 4.25% in Dextrose 20%.

Market Growth Factors

The increasing prevalence of chronic diseases, growing geriatric population, and rising number of surgical procedures are likely to drive the demand for parenteral nutrition solutions in the coming years.

Challenges and Opportunities

Potential challenges include stringent regulatory requirements and the need for specialized healthcare settings for administration. However, these challenges also present opportunities for innovation in product development and delivery systems.

Impact of Recent Healthcare Trends

The parenteral nutrition market, including products like TRAVASOL 4.25% in Dextrose 20%, is influenced by broader healthcare trends.

Personalized Medicine

There's a growing trend towards personalized nutrition solutions, which could impact the development and use of standardized formulations like TRAVASOL 4.25% in Dextrose 20%.

Home Healthcare

The shift towards home healthcare services may influence the demand for parenteral nutrition solutions that can be safely administered outside hospital settings.

Competitive Landscape

While specific competitive data for TRAVASOL 4.25% in Dextrose 20% is not provided, the parenteral nutrition market is generally competitive, with several major pharmaceutical companies offering similar products.

Key Players

Major pharmaceutical companies with established presence in the parenteral nutrition market are likely to continue dominating the space.

Emerging Competitors

Smaller biotech companies and startups focusing on innovative nutrition solutions may enter the market, potentially disrupting established players.

Global Market Dynamics

The demand for parenteral nutrition solutions varies across different regions due to factors such as healthcare infrastructure, economic conditions, and regulatory environments.

Developed Markets

In developed countries, the focus may be on advanced formulations and improved delivery systems for products like TRAVASOL 4.25% in Dextrose 20%.

Emerging Markets

Emerging economies may see increased adoption of parenteral nutrition solutions as healthcare systems improve and awareness of nutritional support in critical care settings grows.

Research and Development Trends

Ongoing research in the field of parenteral nutrition is likely to influence the future of products like TRAVASOL 4.25% in Dextrose 20%.

Novel Ingredients

Research into new amino acid formulations or alternative energy sources could lead to next-generation parenteral nutrition solutions.

Delivery Systems

Innovations in packaging and delivery systems may improve the safety and ease of administration of parenteral nutrition products.

Economic Factors

The market for TRAVASOL 4.25% in Dextrose 20% and similar products is influenced by broader economic trends.

Healthcare Spending

Changes in healthcare budgets and reimbursement policies can impact the adoption and use of parenteral nutrition solutions.

Manufacturing Costs

Fluctuations in raw material costs and production expenses may affect the pricing and availability of products like TRAVASOL 4.25% in Dextrose 20%.

Patient-Centric Approaches

The healthcare industry's shift towards more patient-centric care may influence the development and use of parenteral nutrition solutions.

Quality of Life Considerations

Future research may focus on formulations that not only meet nutritional needs but also improve overall patient comfort and quality of life.

Patient Education

Increased emphasis on patient education about nutritional support may drive demand for more user-friendly parenteral nutrition solutions.

Key Takeaways

• TRAVASOL 4.25% in Dextrose 20% remains a significant player in the parenteral nutrition market.
• While specific recent clinical trials for this product are not mentioned, ongoing research in parenteral nutrition continues to explore optimal formulations and outcomes.
• The market for parenteral nutrition solutions is influenced by factors such as an aging population, increasing chronic diseases, and healthcare trends towards personalized and home-based care.
• Future projections suggest potential growth driven by technological advancements, though challenges like regulatory requirements persist.
• The competitive landscape includes established pharmaceutical companies and potential disruptors focusing on innovative nutrition solutions.
• Global market dynamics vary between developed and emerging markets, with differing focuses on advanced formulations and increased adoption, respectively.
• Research and development trends may lead to novel ingredients and improved delivery systems for parenteral nutrition products.
• Economic factors, including healthcare spending and manufacturing costs, play a crucial role in the market dynamics.
• A shift towards patient-centric approaches may influence future developments in parenteral nutrition solutions.

FAQs

1. What is TRAVASOL 4.25% in Dextrose 20% used for? TRAVASOL 4.25% in Dextrose 20% is a parenteral nutrition solution used to provide essential nutrients intravenously to patients who cannot receive adequate nutrition through oral or enteral routes.

2. How does TRAVASOL 4.25% in Dextrose 20% differ from other parenteral nutrition solutions? TRAVASOL 4.25% in Dextrose 20% contains a specific concentration of amino acids (4.25%) and a high concentration of dextrose (20%), making it suitable for patients with particular nutritional requirements.

3. Are there any ongoing clinical trials specifically for TRAVASOL 4.25% in Dextrose 20%? While the provided information doesn't mention specific ongoing trials for this product, research in the field of parenteral nutrition is continual, potentially including studies on similar formulations.

4. How might future trends in healthcare affect the use of products like TRAVASOL 4.25% in Dextrose 20%? Future trends such as personalized medicine, home healthcare, and patient-centric approaches may influence the development and use of parenteral nutrition solutions, potentially leading to more tailored or user-friendly formulations.

5. What factors could impact the market growth of TRAVASOL 4.25% in Dextrose 20% in the coming years? Factors such as an aging population, increasing prevalence of chronic diseases, technological advancements, regulatory changes, and economic conditions could all impact the market growth of this and similar parenteral nutrition products.

Sources cited: [1] https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-provides-corporate-update-and-2024-outlook [2] https://www.pharmacompass.com/listed-active-pharmaceutical-ingredients/travasol-4-25-in-dextrose-20-in-plastic-container-1 [4] https://ushospitalproducts.baxter.com/sites/g/files/ebysai2186/files/2024-07/USHP%20Supply%20Availability%20Report%20-%20July%2023rd%202024.pdf [9] https://pubmed.ncbi.nlm.nih.gov/6782869/ [10] https://thefdalawblog.com/wp-content/uploads/2021/01/Orange-Book-41st-Annual.pdf